IMMUNO-ONCOLOGY ASSAYS MARKET ANALYSIS

Name: Immuno-Oncology Assays Market News
Creator: Coherent Market Insights
License: https://www.coherentmarketinsights.com/privacy-policy

Immuno-Oncology Assays Market, By Product (Consumables and Software), By Technology (Immunoassay, PCR, NGS, Fow Cytometry, and Others), By Indication (Colorectal Cancer, Lung Cancer, Melanoma, Bladder Cancer, and Others), By Application (Clinical Diagnostics and Research and Development), By Geography (North America, Europe, Asia Pacific, Latin America, Middle East and Africa)

On January 30, 2024, Agilent Technologies Inc., a biotechnology company, announced that it had entered into an agreement with Incyte, a pharmaceutical company, to support the development and commercialization of Incyte’s hematology and oncology portfolio.
In November, 2023, Personalis, Inc., a leader in advanced genomics for precision oncology (Nasdaq: PSNL) and Tempus, a leader in artificial intelligence and precision medicine, announced a strategic collaboration to co-commercialize NeXT Personal Dx, Personalis’ whole genome-based liquid biopsy laboratory developed test (LDT) for detection of molecular residual disease (MRD) and recurrence in cancer.
In April 2023, TORL BioTherapeutics LLC, a biopharmaceutical company, announced a funding of USD 158 Mn to advance development of novel oncology biologics
In April, 2023, Ichor The Institute of Cancer Research, London announced a research collaboration with NeoPhore, an immuno-oncology company, to develop new potential cancer drugs. Under this collaboration The Institute of Cancer Research team will investigate the effect of NeoPhore’s inhibitors on tumours in the laboratory.